Author details

Full Name

Rajesh T Gandhi

Affiliation

ORCID

Career Start Year

1983

Papers

188

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36063397	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022).	Clin Infect Dis	2024
36596305	Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy.	Cell Host Microbe	2023
37581929	The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells.	JCI Insight	2023
37722709	Treatments for COVID-19.		2023
37773595	COVID-19 Therapeutics for Nonhospitalized Patients-Updates and Future Directions.		2023
36508742	Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.		2023
37144613	The severity of COVID-19 across the spectrum of HIV.		2023
36763044	Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy.	J Infect Dis	2023
36877848	HIV post-treatment controllers have distinct immunological and virological features.	Proc Natl Acad Sci U S A	2023
37435958	Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.	Clin Infect Dis	2023
36863066	Seemingly Unrelated Regression Analysis of the Cost and Health-Related Quality of Life Outcomes of the REVAMP Randomized Clinical Trial.		2023
36454551	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.	JAMA	2023
35323030	Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.	AIDS Res Hum Retroviruses	2022
35699707	COVID-19 Treatments for Nonhospitalized Patients-Reply.	JAMA - Journal of the American Medical Association	2022
35381084	Reply to Bottanelli et al.	J Infect Dis	2022
35636911	COVID-19: Where We Are, Where We Need to Be.	Infectious Disease Clinics of North America	2022
35734084	Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system.		2022
35418681	Prolonged viral suppression with anti-HIV-1 antibody therapy.	Nature	2022
35730388	No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART.	AIDS	2022
35545195	First-generation oral antivirals against SARS-CoV-2.	Clin Microbiol Infect	2022
36479541	Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy.		2022
34117753	Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.	Clin Infect Dis	2022
34927686	False-Positive Human Immunodeficiency Virus Test Results in Patients Receiving Lentivirus-Based Chimeric Antigen Receptor T-Cell Therapy: Case Report, Review of the Literature, and Proposed Recommendations.	Journal of Infectious Diseases	2022
34980186	The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study.	Immun Ageing	2022
35029659	COVID-19 Therapeutics for Nonhospitalized Patients.	JAMA - Journal of the American Medical Association	2022
35029644	Realizing the Potential of Anti-SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management.	JAMA - Journal of the American Medical Association	2022
34668010	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords.	Clin Infect Dis	2022
34668008	Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel.	Clin Infect Dis	2022
35140142	Multimodal Investigation of Neuroinflammation in Aviremic Patients With HIV on Antiretroviral Therapy and HIV Elite Controllers.	Neurol Neuroimmunol Neuroinflamm	2022
34755438	Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa.	HIV Medicine	2022
34586088	Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals.	AIDS	2022
35223535	Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients.	Front Cell Infect Microbiol	2022
35176755	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.	Clin Infect Dis	2022
35137129	Associations Between Multiple Measures of HIV-1 Persistence in Persons on Suppressive Antiretroviral Therapy.	Journal of Infectious Diseases	2022
34698502	Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial.	Annals of Internal Medicine	2021
35977180	Disparities in SARS-CoV-2 Vaccination-to-Infection Risk During the COVID-19 Pandemic in Massachusetts.	JAMA Health Forum	2021
33753253	The significance of pressure injuries and purpura in COVID-19 patients hospitalized at a large urban academic medical center: A retrospective cohort study.	Journal of the American Academy of Dermatology	2021
34127579	Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.	AIDS	2021
33539504	Thrombosis and Coronavirus Disease 2019: Controversies and (Tentative) Conclusions.	Clinical Infectious Diseases	2021
33586774	The Search for an HIV Cure: Where Do We Go From Here?	Journal of Infectious Diseases	2021
33472545	Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.	AIDS Res Hum Retroviruses	2021
34136266	Comparison of methods to quantify inducible HIV-1 outgrowth.	Journal of Virus Eradication	2021
33651088	Antiretroviral Drug Recommendations for HIV Treatment and Prevention-Reply.	JAMA	2021
32823274	Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.	J Infect Dis	2021
33035308	Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2: What Goes Around May Come Back Around.	Clinical Infectious Diseases	2021
32640019	Proposing Minimum Requirements for Announcing Clinical Trial Results During the COVID-19 Pandemic.	Clinical Infectious Diseases	2021
32735655	The Multidimensional Challenge of Treating Coronavirus Disease 2019 (COVID-19): Remdesivir Is a Foot in the Door.	Clinical Infectious Diseases	2021
32941052	Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors.	Annals of Internal Medicine	2021
33400687	HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy.	JCI Insight	2021
33395474	When Epidemics Collide: Why People With Human Immunodeficiency Virus May Have Worse Coronavirus Disease 2019 Outcomes and Implications for Vaccination.	Clinical Infectious Diseases	2021